This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Mark Your Calendar for Next Year's Event!
May 9-12, 2022Hynes Convention Center, Boston

Sean Sullivan, Ph.D.
Executive Director, Process Development at Arcturus Therapeutics

Profile

Sean is the Executive Director, Process Development at Arcturus. He has more than 20 years of biotech experience developing nucleic acid based therapeutics, including antisense DNA, ribozymes and plasmid DNA. Most recently, Sean was the Senior Executive Director of Pharmaceutical and Process Development at Vical, Inc. While there, he led a multidisciplinary team within drug substance, drug product and process development. Prior to Vical, Sean was a tenured Associate Professor at the University of Florida in the Department of Pharmaceutics, where he developed a cancer research program focused on inhibiting tumor angiogenesis for the treatment of brain cancer. Prior to that, Sean held various positions at Valentis, Cell Genesys, Ribozyme Pharmaceuticals, Vestar and was a post doctoral fellow at the California Institute of Technology. In prior roles, Sean held the position of Principal Investigator for NIH funded projects developing a genital herpes simplex virus vaccine and enzymatically synthesized linear DNA expression cassettes. Sean holds a Ph.D. and Master of Science degree in Biochemistry from the University of Tennessee, and Bachelors of Science degree in Chemistry from Marysville College.


https://arcturusrx.com/about-arcturus/our-team/

Agenda Sessions

  • ROOM 205C: Preclinical Immunogenicity Characterization of ARCT-021 SARS-CoV-2 Vaccine

    9:30am
  • Preclinical Immunogenicity Characterization of ARCT-021 SARS-CoV-2 Vaccine

    1:30pm